BSX bostonscientific.com: Forward P/S Multiple
Mass procurement of innovative catheters and stents by global clinics is driving the expansion of Boston Scientific (BSX). The expected price-to-sales ratio listed on GURU.Markets confirms the impact of high demand for high-margin neuromodulation systems, with the metric holding around 2.40. The rise in share prices is based on FDA approvals and the expansion of its international presence, which strengthens the fundamental resilience of the business.
Metric breakdowns and analytics for Boston Scientific Corporation Inc. (BSX)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
Total Debt to Capital Boston Scientific|BSX - Long-Term Debt to Capital|Short-Term Debt to Equity Boston Scientific|BSX - Company Debts|Debt to Book Value Boston Scientific Corporation Inc.|BSX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Boston Scientific|Quick Liquidity bostonscientific.com
- financial results and valuation multiples details:
BSX - Annual Net Income|Future Profit Boston Scientific|BSX - P/E Multiple|Forward P/E Multiple Boston Scientific Inc|BSX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Boston Scientific Corporation Inc.|BSX - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Boston Scientific|BSX - Net earnings per share for the last 12 months|Quarterly EPS earnings growth bostonscientific.com|BSX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Boston Scientific
- sales volume and revenue indicators:
Summary company analytics:Boston Scientific Corporation (BSX)
To assess the credit quality of Boston Scientific (BSX), the analyst compares market capitalization with expected sales volumes. Business resilience is driven by demand for cardiovascular surgeries and regulatory approval of new medical devices. By analyzing the projected P/S dynamics, the investor determines the risk of asset overvaluation: an inflated ratio leaves quotes vulnerable to any revenue misses, whereas low values reduce the probability of a collapse.
Key competitors
Forward P/S Multiple EW (Edwards Lifesciences Corporation)|ResMed Inc (RMD) - Market Cap to Future Revenue Ratio|OmniPod - Forward P/S Multiple|ZBH (Zimmer Biomet Holdings) - Market Cap to Projected Revenue|COO: Forward P/S Multiple|ALGN - Market Cap to Expected Sales Ratio|GMED (Globus Medical) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TransMedics Group Inc (TMDX)|Forward P/S Multiple ATEC|Forward P/S Multiple Artivion Corp (AORT)|Price-to-Projected Revenue Ratio Enovis Corporation ENOV|integralife.com - Price-to-Projected Revenue Ratio|ESTA: Forward Price-to-Revenue Multiple|Forward Price to Sales BBNX (Beta Bionics, Inc.)|IRMD: Forward P/S Multiple|Market Cap to Future Revenue Ratio Embecta Health (EMBC)|Price-to-Projected Revenue Ratio Tandem Diabetes Care|AXGN - Projected Price to Revenue|Forward Price-to-Revenue Multiple SIBN (SI-BONE)|Forward P/S Multiple Orthofix Medical (OFIX)|Forward P/S Multiple BVS (Bioventus Corp)|Market Cap to Expected Sales Ratio OrthoPediatrics Corp (KIDS)|TMCI - Price-to-Projected Revenue Ratio|Future Price to Revenue SRTA|Carlsmed (CARL) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple RxSight Inc|CLPT (ClearPoint Neuro Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stereotaxis Corporation STXS|Price-to-Projected Revenue Ratio Neuronetics, Inc. (STIM)|sightsciences.com - Market Cap to Projected Revenue|Orchestra BioMed, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ANIK (Anika Therapeutics Inc.)|InspireMD Corp - Forward P/S Multiple|ZJYL: Price-to-Projected Revenue Ratio|vivani.com (VANI) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Xtant Medical (XTNT)|Price-to-Projected Revenue Ratio NeuroOne Medical Technologies Corporation|Modular Med (MODD) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MYO (Myomo, Inc)|Price to Expected Revenue Ratio COCH|Price-to-Projected Revenue Ratio Vivos Therapeutics VVOS|envveno.com (NVNO) - Market Cap to Future Revenue Ratio|SINT - Price-to-Projected Revenue Ratio|TNON (Tenon Medical Inc.) - Market Cap to Projected Revenue|LFWD (ReWalk Robotics Ltd) - Forward Price-to-Revenue Multiple|Autonomix Medical - Forward Price to Sales|Price-to-Projected Revenue Ratio INVO Fertility Inc|bonebiologics.com (BBLG) - Market Cap to Expected Sales Ratio|Forward P/S Multiple AXNX|Forward Price-to-Revenue Multiple BIOLASE Inc. BIOL|Forward P/S Multiple DYNT (Dynatronics)|Market Cap to Expected Sales Ratio Paragon 28 Inc. (FNA)|INVO Bio - Forward P/S Multiple
